References
- Kirshenbaum AS, Goff JP, Semere T, et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999;94:2333–2342
- Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol 2004;4:787–799
- Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005;6:135–142
- Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008;454:445–454
- Metcalfe DD. Mast cells and mastocytosis. Blood 2008;112:946–956
- Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res 2013;3:159–172
- Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukemia Res 2001;25:603–625
- Ren H, Tan X, Dong Y, et al. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells. Basic Clin Pharmacol Toxicol 2009;104:241–252
- Kosior K, Lewandowska-Grygiel M, Giannopoulos K. Tyrosine kinase inhibitors in hematological malignancies. Postepy Hig Med Dosw 2011;65:819–828
- Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007;104:13283–13288
- Gleixner KV, Mayerhofer M, Cerny-Reiterer S, et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 2011;118:1885–1898
- Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leukemia Res 2011;35:1143–1152
- Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007;92:1451–1459
- Lober K, Alfonso A, Escribano L, Botana LM. STI571 (Glivec) affects histamine release and intracellular pH after alkalinisation in HMC-1560, 816. J Cell Biochem 2008;103:865–876
- Tobio A, Alfonso A, Botana LM. PKC potentiates tyrosine kinase inhibitors STI571 and dasatinib cytotoxic effect. Anticancer Res 2014;34:3347–3356
- Tobio A, Alfonso A, Botana LM. Cross-talks between c-Kit and PKC isoforms in HMC-1560 and HMC-1560,816 cells. Different role of PKCδ in each cellular line. Cell Immunol 2015;293:104–112
- Shore PA. The chemical determination of histamine. Methods Biochem Anal 1971:89–97
- Wan BC, Peh KH, Pearce FL, Assem ES. Effects of genistein on rat ileum smooth muscle contraction and histamine release from rat peritoneal mast cells. Inflamm Res 2005;54(Suppl. 1):S09–S10
- Blank U, Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol 2004;25:266–273
- Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006;107:752–759
- Lober K, Alfonso A, Escribano L, Botana LM. Influence of the tyrosine kinase inhibitors STI571 (Glivec), lavendustin A and genistein on human mast cell line (HMC-1(560)) activation. J Cell Biochem 2008;103:1076–1088
- Krauth MT, Mirkina I, Herrmann H, et al. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Expt Aller 2009;39:1711–1720
- Kneidinger M, Schmidt U, Rix U, et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 2008;111:3097–3107
- Brazzelli V, Grasso V, Borroni G. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol 2013;27:1471–1480
- Poole AW, Pula G, Hers I, et al. PKC-interacting proteins: from function to pharmacology. Trends Pharmacol Sci 2004;25:528–535
- Basu A, Pal D. Two faces of protein kinase Cdelta: the contrasting roles of PKCdelta in cell survival and cell death. ScientificWorldJournal 2010;10:2272–2284
- Kilpatrick LE, Lee JY, Haines KM, et al. A role for PKC-delta and PI 3-kinase in TNF-alpha-mediated antiapoptotic signaling in the human neutrophil. Am J Physiol Cell Physiol 2002;283:C48–C57